公开(公告)号：WO2011068723A1

公开(公告)日：2011-06-09

申请号：PCT/US2010/057818

申请日：2010-11-23

Applicant: ABBOTT LABORATORIES ,  ABBOTT GMBH & CO.KG ,  ROTH, Wolfgang ,  BURST, Alexander ,  ZIETSCH, Martina ,  LIU, Wei ,  DUTTA, Sandeep

Inventor： ROTH, Wolfgang ,  BURST, Alexander ,  ZIETSCH, Martina ,  LIU, Wei ,  DUTTA, Sandeep

IPC: A61K9/20 ,  A61K9/14 ,  A61K31/277 ,  A61K31/167 ,  A61K31/192 ,  A61K31/485

CPC classification number: A61K9/2027 ,  A61K9/2031 ,  A61K9/2054 ,  A61K9/209 ,  A61K9/2095 ,  A61K31/167 ,  A61K31/192 ,  A61K31/277 ,  A61K31/485

Abstract: The present invention relates to compositions for oral administration. The invention preferably comprises at least one abuse - resistant drug delivery composition for delivering a drug having potential for dose dumping in alcohol, related methods of preparing these dosage forms, and methods of treating a patient in need thereof comprising administering the inventive compositions to the patient. The dosage form can include verapamil. These formulations have reduced potential for abuse. In another formulation, preferably the abuse relevant drug is an opioid and the non- abuse relevant drug is acetaminophen or ibuprofen. More preferably, the opioid is hydrocodone, and the non -abuse relevant analgesic is acetaminophen. In certain preferred embodiments, the dosage forms are characterized by resistance to solvent extraction; tampering, crushing or grinding. Certain embodiments of the inventions provide dosage forms that provide an initial burst of release of drug followed by a prolonged period of controllable drug release.

Abstract translation: 本发明涉及用于口服给药的组合物。 本发明优选包含至少一种用于递送在醇中具有剂量倾倒潜力的药物递送组合物，制备这些剂型的相关方法以及治疗有需要的患者的方法包括向患者施用本发明组合物 。 剂型可以包括维拉帕米。 这些制剂减少了滥用的可能性。 在另一种制剂中，优选滥用相关药物是阿片样物质，非滥用相关药物是对乙酰氨基酚或布洛芬。 更优选地，阿片样物质是氢可酮，非相关镇痛药是对乙酰氨基酚。 在某些优选的实施方案中，剂型的特征在于耐溶剂萃取; 篡改，破碎或研磨。 本发明的某些实施方案提供剂型，其提供药物释放的初始爆发，随后延长药物释放时间。

公开(公告)号：WO2008067164A2

公开(公告)日：2008-06-05

申请号：PCT/US2007/084617

申请日：2007-11-14

Applicant: ABBOTT LABORATORIES ,  BERNDL, Gunther ,  ROSENBERG, Joerg ,  FASTNACHT, Katja ,  LIEPOLD, Bernd ,  BREITENBACH, Joerg ,  JUNG, Tina ,  ROTH, Wolfgang ,  MORRIS, John ,  KLEIN, Cheri, E. ,  CAI, Yan ,  ALANI, Laman ,  GHOSH, Soumojeet

Inventor： BERNDL, Gunther ,  ROSENBERG, Joerg ,  FASTNACHT, Katja ,  LIEPOLD, Bernd ,  BREITENBACH, Joerg ,  JUNG, Tina ,  ROTH, Wolfgang ,  MORRIS, John ,  KLEIN, Cheri, E. ,  CAI, Yan ,  ALANI, Laman ,  GHOSH, Soumojeet

IPC: A61K9/20 ,  A61K31/427

CPC classification number: A61K31/427 ,  A61K9/146 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2077 ,  A61K9/2095

Abstract: The present invention features solid pharmaceutical dosage formulations comprising ritonavir. As a non-limiting example, a dosage form of the present invention comprises a solid dispersion or solid solution of ritonavir in a matrix, where the matrix comprises at least one water-soluble polymer, such as copovidone, and at least one surfactant, such as polyoxyl 40 hydrogenated castor oil or macrogolglycerol hydroxystearate. Preferably, the solid dispersion or solution does not include, or includes only an insignificant amount of, PEG.

Abstract translation: 本发明的特征在于包含利托那韦的固体药物剂型。 作为非限制性实例，本发明的剂型包含利托那韦在基质中的固体分散体或固体溶液，其中基质包含至少一种水溶性聚合物如共聚维酮，和至少一种表面活性剂，例如 作为聚氧乙烯40氢化蓖麻油或聚乙二醇羟基硬脂酸酯。 优选地，固体分散体或溶液不包括或仅包含不显着量的PEG。

公开(公告)号：EP2112925A2

公开(公告)日：2009-11-04

申请号：EP07871461.5

申请日：2007-11-14

Applicant: Abbott Laboratories

Inventor： BERNDL, Gunther ,  ROSENBERG, Joerg ,  FASTNACHT, Katja ,  LIEPOLD, Bernd ,  BREITENBACH, Joerg ,  JUNG, Tina ,  ROTH, Wolfgang ,  MORRIS, John ,  KLEIN, Cheri E. ,  CAI, Yan ,  ALANI, Laman ,  GHOSH, Soumojeet

IPC: A61K9/28 ,  A01N43/54 ,  A01N43/78

CPC classification number: A61K31/427 ,  A61K9/146 ,  A61K9/1617 ,  A61K9/1635 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2077 ,  A61K9/2095

Abstract: The present invention features solid pharmaceutical dosage formulations comprising ritonavir. As a non-limiting example, a dosage form of the present invention comprises a solid dispersion or solid solution of ritonavir in a matrix, where the matrix comprises at least one water-soluble polymer, such as copovidone, and at least one surfactant, such as polyoxyl 40 hydrogenated castor oil or macrogolglycerol hydroxystearate. Preferably, the solid dispersion or solution does not include, or includes only an insignificant amount of, PEG.